PDCD1 and neoplasm: This may be due to PD-L1 in the cancer cells binding to the PD-1 receptor on tumor-specific T cells, which requires an increase in PD-1 levels to compensate for the rise in PD-L1 levels, allowing the cancer cells to evade the immune system.